“If we don’t address stewardship, we are doomed to failure.”
Director of the Center for Disease Dynamics,
Economics and Policy
The leading factor in the emergence of antibiotic resistance is the inappropriate use of antimicrobial medicines in both humans and animals. Antibiotic stewardship programs aim to ensure that patients benefit from the most effective antibiotic treatments, while helping to curb resistance and limit the side effects and costs of unnecessary treatments.
What is antimicrobial stewardship?
Antimicrobial stewardship is defined as a program which seeks to ensure that the right antibiotic is given to the right patient at the right time, with the right dose and the right route, causing the least harm to the patient and future patients. In realistic terms, it is a multidisciplinary approach that aims to ensure that patients benefit from the most effective antibiotic treatments, while limiting the side effects and costs of unnecessary treatments.
Successful antimicrobial stewardship programs require a continued and diligent interaction between all levels of healthcare providers, including physicians, infectious disease specialists, infection control practicioners, nursing staff, pharmacists, microbiologists, pathologists, lab directors and healthcare administrators.
The core elements of antimicrobial stewardship programs include:
- Implementation of national and international guidelines and clinical pathways for the diagnosis and treatment of infectious diseases
- Limiting the use of antibiotics where not needed or not indicated
- Delivering the most appropriate antibiotic, with the correct dose established according to the type and site of infection, patient’s age, weight and clinical situation
- Switching antibiotics from parenteral to oral form as soon as possible
- Timely conversion to the most narrow antibiotic spectrum according to the organism susceptibility
- Use of the shortest effective antibiotic course and discontinuation of antibiotic courses as soon as possible
First global surveys
The Global Antimicrobial Resistance Surveillance System (GLASS), launched in 2018 by World Health Organization, aims to enable standardized and comparable data on emerging forms of AMR to be collected, analyzed and shared internationally.
The first GLASS report has revealed widespread and high levels of resistance in 25 high-income, 20 middle-income and 7 low-income countries.
(GLASS report: Early implementation 2016-2017)
The Global Point Prevalence Survey of Antimicrobial Consumption and Resistance (GLOBAL-PPS) uses the European Surveillance of Antimicrobial Consumption Point Prevalence Surveillance method of data collection to monitors global rates of antimicrobial utilization and resistance in hospitalized patients. bioMérieux is the unique sponsor of the GLOBAL-PPS initiative.
It’s everyone’s concern!
Healthcare providers have an essential role to play in the appropriate use of these drugs to contain the emerging antibiotic resistance problem. Rapid, high medical value diagnostics in conjunction with Antimicrobial Stewardship Programs can be used to support relevant decisions to withhold, de-escalate or stop antibiotic treatment earlier. Antimicrobial Stewardship Programs encourage rational prescribing of antibiotics and remind healthcare workers – and their patients – of the consequences of antibiotic over-use and misuse. In fact, we all need to change our views on antibiotics and reconsider them as shared non-renewable resources, which must be preserved.
While the optimal approach to effective antimicrobial stewardship remains elusive and may vary significantly between settings, a wide array of studies and reviews from diverse healthcare contexts have demonstrated the positive impact of stewardship programs on limiting antibiotic resistance. Huttner B et al. Success stories of implementation of antimicrobial stewardship: a narrative review. Clinical Microbiology and Infection 2014;20:954-962. DOI:10.1111/1469-0691.12803
Preserving antibiotic efficacy
The report entitled The State of the World’s Antibiotics 2015, published by the Center for Disease Dynamics, Economics & Policy (The Center for Disease Dynamics, Economics & Policy), stated that incentives have focused on the development of new antibiotics, but insufficient attention has been paid to conserving the effectiveness of our existing antibiotic arsenal. Global antibiotic stewardship in the broadest sense should make it possible not only to conserve the current effectiveness of existing antibiotics, but even to reclaim some of the effectiveness that has been lost through bacterial mutations.
Report co-author and The Center for Disease Dynamics, Economics & Policy Director Ramanan Laxminarayan believes that 80% of our global resources for controlling AMR should be focused on antimicrobial stewardship, and no more than 20% on drug development; because no matter how many new drugs come out, they will all generate resistant bacterial mutants if we continue to misuse them.
Stewardship guidelines and recommendations
State-of-the-art guidelines and information are essential for antimicrobial stewardship programs.
In 2016, the Infectious Diseases Society of America and the American Thoracic Society published new guidelines recommending a shorter duration of antibiotic treatment in adults with two common hospital-acquired infections: ventilator-associated pneumonia and hospital-acquired pneumonia. Shortening the course of antibiotic treatment reduces the potential for antibiotic resistance, while maintaining the benefit of the treatment. The new guidelines also recommend that hospitals use antibiograms to determine the most appropriate treatment.
A World Health Organization expert panel has updated the list of antibiotics considered most important to human medicine Collignon PC et al. World Health Organization Ranking of Antimicrobials According to Their Importance in Human Medicine: A Critical Step for Developing Risk Management Strategies to Control Antimicrobial Resistance From Food Animal Production. Clin Infect Dis. 2016; 63 (8): 1087-1093. DOI: 10.1093/cid/ciw475. Fluoroquinolones, macrolides, third-generation cephalosporins, glycopeptides and carbapenems are identified as the highest priority antibiotics to be preserved. The list is intended to support stewardship efforts, particularly in the context of animal farming.
Success factors of a hospital-based antimicrobial stewardship program
- Establish a clear aim/vision that is shared by all stakeholders and that conveys a sense of urgency. Stewardship should be a patient safety priority.
- Seek management support, accountability and secure funding.
- Assemble a strong coalition including a multi-professional antimicrobial stewardship team with an influential clinical leader.
- Establish effective communication structures within your hospital.
- Start with core evidence-based stewardship interventions depending on local needs, geography and resources and set up measurement strategies to demonstrate their impact.
- Ensure that all healthcare staff are aware of the importance of hospital-based antimicrobial stewardship. Empower them to act and to support others using a range of effective advocacy tools.
- Ensure early or short-term wins and then consolidate success/gains while progressing with further change and innovation.
Source: “Practical Guide to Antimicrobial Stewardship in Hospitals” bioMérieux.
ANTIMICROBIAL STEWARDSHIP A practical guide to implementation in hospitals
CLASSIFICATION OF ANTIBIOTICS ACCORDING TO WHO’S ESSENTIAL MEDICINE LIST
In 2017, new advice on which antibiotics to use for common infections and which to preserve for the most serious circumstances was among the additions to the World Health Organization Model list of essential medicines. This list is used by many countries to increase access to medicines and guide decisions about which products they ensure are available for their populations. World Health Organization experts grouped antibiotics used to treat 21 of the most common general infections into three categories: ACCESS, WATCH and RESERVE groups.
> More details on antibiotics classification